CareDx, Inc. (CDNA) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, CareDx, Inc.'s filing signal turned positive.

CareDx is a precision medicine company focused on improving outcomes for transplant patients and advancing organ health through its integrated suite of non-invasive molecular testing, laboratory products, digital health technologies, and patient support solutions. The company is a leader in providing genomics-based information for transplant patients, with its primary testing services including AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare, and AlloSure Lung. CareDx operates with a differentiated go-to-market strategy for laboratory-developed tests (LDTs), serving a concentrated market of transplant centers with a portfolio of solutions to increase adoption and lower revenue acquisition costs. Its growth strategy centers on accelerating profitable growth, driving operational excellence, expanding its total addressable market through the TRANSPLANT+ initiative, and elevating its performance culture. The company's operations are primarily located in the United States and Sweden, with substantially all revenues generated from the United States and Europe.

Revenue is primarily driven by the sale of testing services, including AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare, and AlloSure Lung, as well as product sales and patient and digital solutions.